Mantle cell lymphoma epidemiology and demographics

	Mantle cell lymphoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Mantle cell lymphoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Mantle cell lymphoma epidemiology and demographics On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Mantle cell lymphoma epidemiology and demographics All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Mantle cell lymphoma epidemiology and demographics
on Mantle cell lymphoma epidemiology and demographics
Mantle cell lymphoma epidemiology and demographics in the news
Blogs on Mantle cell lymphoma epidemiology and demographics
Directions to Hospitals Treating Mantle cell lymphoma
Risk calculators and risk factors for Mantle cell lymphoma epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ali Akram, M.B.B.S.[2]

Overview

Mantle cell lymphoma accounts for 4–8% of all adult non-Hodgkin lymphoma (NHL). It has an incidence of approximately 1-2 per 100,000 individuals worldwide. The male to female ratio is approximately 4 to 1 and the median age is about 60 years.

Epidemiology and Demographics

Incidence

The annual incidence of mantle cell lymphoma has increased during recent decades to 1–2 per 100,000 individuals worldwide.^[1]

Age

The median age at diagnosis for mantle cell lymphoma is about 60 years.^[2]

Race

Mantle cell lymphoma tends to affect Caucasians more than African-Americans.^[3]

Gender

Males are more commonly affected by mantle cell lymphoma than females. The male to female ratio is approximately 4 to 1.^[4]

References

↑ M. Dreyling, C. Geisler, O. Hermine, H. C. Kluin-Nelemans, S. Le Gouill, S. Rule, O. Shpilberg, J. Walewski & M. Ladetto (2014). "Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Annals of oncology : official journal of the European Society for Medical Oncology. 25 Suppl 3: iii83–iii92. doi:10.1093/annonc/mdu264. PMID 25210087. Unknown parameter |month= ignored (help)
↑ Arati A. Inamdar, Andre Goy, Nehad M. Ayoub, Christen Attia, Lucia Oton, Varun Taruvai, Mark Costales, Yu-Ting Lin, Andrew Pecora & K. Stephen Suh (2016). "Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents". Oncotarget. 7 (30): 48692–48731. doi:10.18632/oncotarget.8961. PMID 27119356. Unknown parameter |month= ignored (help)
↑ Yuhong Zhou, Haijun Wang, Wenjing Fang, Jorge E. Romaguer, Yanxia Zhang, Kay B. Delasalle, Larry Kwak, Qing Yi, Xianglin L. Du & Michael Wang (2008). "Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004". Cancer. 113 (4): 791–798. doi:10.1002/cncr.23608. PMID 18615506. Unknown parameter |month= ignored (help)
↑ Arati A. Inamdar, Andre Goy, Nehad M. Ayoub, Christen Attia, Lucia Oton, Varun Taruvai, Mark Costales, Yu-Ting Lin, Andrew Pecora & K. Stephen Suh (2016). "Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents". Oncotarget. 7 (30): 48692–48731. doi:10.18632/oncotarget.8961. PMID 27119356. Unknown parameter |month= ignored (help)

Template:Hematology

Template:WH Template:WS

[1] M. Dreyling, C. Geisler, O. Hermine, H. C. Kluin-Nelemans, S. Le Gouill, S. Rule, O. Shpilberg, J. Walewski & M. Ladetto (2014). "Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Annals of oncology : official journal of the European Society for Medical Oncology. 25 Suppl 3: iii83–iii92. doi:10.1093/annonc/mdu264. PMID 25210087. Unknown parameter |month= ignored (help)

[2] Arati A. Inamdar, Andre Goy, Nehad M. Ayoub, Christen Attia, Lucia Oton, Varun Taruvai, Mark Costales, Yu-Ting Lin, Andrew Pecora & K. Stephen Suh (2016). "Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents". Oncotarget. 7 (30): 48692–48731. doi:10.18632/oncotarget.8961. PMID 27119356. Unknown parameter |month= ignored (help)

[3] Yuhong Zhou, Haijun Wang, Wenjing Fang, Jorge E. Romaguer, Yanxia Zhang, Kay B. Delasalle, Larry Kwak, Qing Yi, Xianglin L. Du & Michael Wang (2008). "Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004". Cancer. 113 (4): 791–798. doi:10.1002/cncr.23608. PMID 18615506. Unknown parameter |month= ignored (help)

[4] Arati A. Inamdar, Andre Goy, Nehad M. Ayoub, Christen Attia, Lucia Oton, Varun Taruvai, Mark Costales, Yu-Ting Lin, Andrew Pecora & K. Stephen Suh (2016). "Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents". Oncotarget. 7 (30): 48692–48731. doi:10.18632/oncotarget.8961. PMID 27119356. Unknown parameter |month= ignored (help)

[1]

[2]

[3]

[4]